|
Jan 31
|
Novartis (NVS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Jan 31
|
Novartis Shares Fall After Earnings Miss Hopes, Outlook Disappoints
|
|
Jan 31
|
Those who invested in Novartis (VTX:NOVN) three years ago are up 37%
|
|
Jan 31
|
Novartis misses Q4 profit expectations as costs disappoint
|
|
Jan 31
|
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
|
|
Jan 30
|
Top 15 Best-Selling Cancer Drugs
|
|
Jan 30
|
Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK
|
|
Jan 30
|
15 Best Annual Dividend Stocks To Buy Now
|
|
Jan 30
|
CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
|
|
Jan 29
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Jan 16
|
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
|
|
Jan 16
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.
|
|
Jan 12
|
Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jan 12
|
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
|
|
Jan 11
|
Novartis (NVS) Gains As Market Dips: What You Should Know
|
|
Jan 11
|
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
|
|
Jan 11
|
Cytokinetics, Albertsons, Kroger, Boeing: Trending tickers
|
|
Jan 11
|
UPDATE 1-Novartis drops pursuit of Cytokinetics - WSJ
|
|
Jan 11
|
Novartis Pursuit of Cytokinetics Cools
|
|
Jan 10
|
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
|